Sanara MedTech Inc. SMTI
35.06
(0.04)
(0.11%)
as of 25 Sep
- Market cap
- $322.5M
- P/E
- 0.0×
Follow SMTI
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.86 | 1.39 | 1.95 | 2.69 | |
P/FCF ratio |
45.85 | 44.97 | 92.62 | 0.00 | |
P/Operating CF |
100.25 | (60.67) | 51.04 | 126.06 | |
P/B ratio |
25.76 | 21.31 | 33.96 | 44.68 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.15 | 1.70 | 2.25 | 3.00 | |
EV/EBITDA |
20.33 | 14.28 | 20.09 | 18.74 | |
EV/Operating CF |
41.50 | 28.98 | 34.14 | 80.94 | |
EV/FCF |
53.03 | 55.06 | 106.57 | (368.45) | |
Quick Ratio |
2.24 | 1.99 | 1.53 | 1.56 | |
Current Ratio |
2.58 | 2.28 | 1.80 | 1.80 | |
Net Debt/EBITDA |
12.56 | 9.87 | 16.40 | 7.44 | |
Debt/Assets |
67.22% | 66.73% | 63.02% | 63.43% | |
Debt/Equity |
5.86 | 6.59 | 7.75 | 7.34 | |
Asset Turnover |
1.31 | 1.30 | 1.28 | 1.28 | |
Operating CF/Net income |
(4.50) | (5.37) | (2.45) | (0.07) | |
Capex/Depreciation |
(0.01) | (0.07) | (0.11) | (0.95) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4.10% | 2.73% | 7.39% | 3.91% | |
Selling, General and Administrative Expense of Revenue |
80.33% | 78.71% | 72.88% | 75.48% | |
Intangible Assets out of Total Assets |
0.30 | 0.31 | 0.30 | 0.35 | |
Share Based Compensation of Revenue |
5.32% | 3.70% | 4.29% | 4.68% | |
Graham Net Nets |
(0.14) | (0.21) | (0.17) | (0.12) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(15.73%) | (22.64%) | (18.63%) | (13.68%) | |
Free Cash Flow Yield |
2.18% | 2.22% | 1.08% | (0.30%) | |
Revenue per Share |
3.25 | 3.19 | 3.19 | 3.05 | |
Operating CF per Share |
0.24 | (0.28) | 0.46 | 0.25 | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.12) | |
Free Cash Flow per Share |
0.23 | (0.29) | 0.45 | 0.13 | |
Cash per Share |
1.78 | 1.56 | 1.92 | 1.73 | |
Shareholders Equity per Share |
0.92 | 0.81 | 0.69 | 0.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.92 | 0.81 | 0.69 | 0.71 | |
Free Cash Flow |
2.03 | (2.51) | 3.86 | 1.12 | |
Working Capital |
19.71 | 17.50 | 14.92 | 13.87 | |
Capital Expenditures |
(0.01) | (0.04) | (0.08) | (1.06) | |
Net Current Asset Value |
(29.01) | (31.06) | (33.47) | (33.72) | |
EV/EBIT |
28.07 | 20.07 | 31.72 | 27.39 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.04 | |
Net Profit Margin |
(1.61%) | 1.65% | (5.84%) | (115.48%) | |
Price to Operating Income |
24.27 | 16.39 | 27.56 | 24.61 | |
| Other line items | |||||
Average Receivables |
12.29 | 12.76 | 12.22 | 11.60 | |
Average Payables |
1.45 | 1.53 | 1.93 | 1.31 | |
Average Inventory |
3.49 | 3.14 | 3.35 | 3.20 | |
Average Assets |
83.96 | 82.83 | 80.52 | 79.82 | |
Average Common Equity |
21.66 | 21.84 | 22.42 | 22.80 |
Columns are period end dates